Beyond monoclonal gammopathy of undetermined significance, clinical spectrum of immunoglobulin M gammopathy: a case series with focus on the diagnostic and management challenges [0.03%]
超出意义未明的单克隆免疫球蛋白血症的免疫球蛋白M系单克隆免疫球蛋白血症的临床谱系：以诊断和管理挑战为重点的病例系列分析
Omer S Ashruf,Saeid Mirzai,Laeth L George et al.
Omer S Ashruf et al.
Immunoglobulin M monoclonal gammopathy is detected in Waldenström macroglobulinemia (WM), a rare lymphoplasmacytic lymphoma with serum immunoglobulin M. We report three rare presentations with focus on diagnostic and management challenges ...
Binsah George,Binoy Yohannan,Virginia Mohlere et al.
Binsah George et al.
Therapy-related acute myeloid leukemia (t-AML) usually stems from exposure of the bone marrow to cytotoxic chemotherapy and/or radiation therapy. t-AML is usually associated with poor overall survival, but occasionally t-AML can involve fav...
Improved survival of adolescents and young adults patients with T-cell acute lymphoblastic leukemia [0.03%]
T细胞急性淋巴细胞白血病青少年和年轻成人患者预后的改善
Amr Hanbali,Ahmed Kotb,Riad El Fakih et al.
Amr Hanbali et al.
Aim: The outcome of T-cell acute lymphoblastic leukemia (T-ALL) has improved with the use of pediatric-inspired protocols in the adolescents and young adults (AYA) population. There is limited literature regarding the out...
Ahmed Alnughmush,Riad El Fakih,Shamayel Mohammed et al.
Ahmed Alnughmush et al.
Pediatric-type follicular lymphoma is an uncommon and newly recognized entity of lymphoid neoplasm commonly encountered in the young population. Despite its indolent clinical course and localized nodal involvement, it has been characterized...
Turkey real-life data: demographic features, treatment results and effects of comorbidities in chronic myeloid leukemia [0.03%]
土耳其真实世界数据：慢性髓性白血病的流行特征、治疗结果及合并症的影响
Guray Saydam,Ali Unal,Ibrahim Celalettin Haznedaroglu et al.
Guray Saydam et al.
Aim: This study aimed to identify patient characteristics, treatment patterns and outcomes and to evaluate the effects of presence of comorbidities at diagnosis in chronic phase (CP)-chronic myeloid leukemia (CML) patient...
The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia [0.03%]
共病对慢性髓性白血病患者酪氨酸激酶抑制剂选择的影响
Guray Saydam,Ridvan Ali,Ahmet Muzaffer Demir et al.
Guray Saydam et al.
Tyrosine kinase inhibitors (TKIs) approved for chronic myeloid leukemia known to have similar efficacies but different safety profiles. Therefore, the choice of patient-specific treatments is driven by factors such as tolerability and adver...
Adhesion molecules in multiple myeloma oncogenesis and targeted therapy [0.03%]
黏附分子在多发性骨髓瘤肿瘤发生及靶向治疗中的作用
Maroun Bou Zerdan,Lewis Nasr,Joseph Kassab et al.
Maroun Bou Zerdan et al.
Every day we march closer to finding the cure for multiple myeloma. The myeloma cells inflict their damage through specialized cellular meshwork and cytokines system. Implicit in these interactions are cellular adhesion molecules and their ...
The use of hypomethylating agents in hematologic malignancies: treatment preferences and results [0.03%]
低甲基化药物在血液系统恶性肿瘤中的应用：治疗偏好与结果分析
Istemi Serin,Mehmet Hilmi Dogu
Istemi Serin
Aim: The objective of this article was to compare the efficiency of azacitidine (AZA) and decitabine (DAC) in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) who are not suitable for high-dos...
Iron overload during the treatment of acute leukemia: pretransplant transfusion experience [0.03%]
急性白血病治疗过程中的铁过载：移植前输血经验
Osman Yokus,Celalettin Herek,Tahir Alper Cinli et al.
Osman Yokus et al.
Background: Recent studies have shown the increased risk of mortality in cases with acute leukemia and iron overload. We aimed to determine the status of iron overload in patients with acute leukemia. ...
A Phase I trial of talazoparib in patients with advanced hematologic malignancies [0.03%]
塔拉佐帕利在血液系统恶性肿瘤患者中的一项一期试验
Ajay K Gopal,Rakesh Popat,Ryan J Mattison et al.
Ajay K Gopal et al.
Aim: The objective of this study was to establish the maximum tolerated dose (MTD), safety, pharmacokinetics, and anti-leukemic activity of talazoparib. P...